PL376867A1 - Pochodne indolilo-pirazynonu przydatne w leczeniu zaburzeń hiperproliferacyjnych i chorób związanych z angiogenezą - Google Patents
Pochodne indolilo-pirazynonu przydatne w leczeniu zaburzeń hiperproliferacyjnych i chorób związanych z angiogeneząInfo
- Publication number
- PL376867A1 PL376867A1 PL376867A PL37686703A PL376867A1 PL 376867 A1 PL376867 A1 PL 376867A1 PL 376867 A PL376867 A PL 376867A PL 37686703 A PL37686703 A PL 37686703A PL 376867 A1 PL376867 A1 PL 376867A1
- Authority
- PL
- Poland
- Prior art keywords
- angiogenesis
- indolyl
- diseases associated
- proliferative disorders
- derivatives useful
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- YVFNMQLTCRSZOJ-UHFFFAOYSA-N 3-(1h-indol-2-yl)-1h-pyrazin-2-one Chemical class O=C1NC=CN=C1C1=CC2=CC=CC=C2N1 YVFNMQLTCRSZOJ-UHFFFAOYSA-N 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000003463 hyperproliferative effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42549002P | 2002-11-12 | 2002-11-12 | |
| US46091503P | 2003-04-07 | 2003-04-07 | |
| US48420203P | 2003-06-30 | 2003-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL376867A1 true PL376867A1 (pl) | 2006-01-09 |
Family
ID=32314888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL376867A PL376867A1 (pl) | 2002-11-12 | 2003-11-10 | Pochodne indolilo-pirazynonu przydatne w leczeniu zaburzeń hiperproliferacyjnych i chorób związanych z angiogenezą |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1565455A1 (es) |
| JP (1) | JP2006509840A (es) |
| KR (1) | KR20050072824A (es) |
| AR (1) | AR043059A1 (es) |
| AU (1) | AU2003290744A1 (es) |
| BR (1) | BR0316169A (es) |
| CA (1) | CA2505819A1 (es) |
| EC (1) | ECSP055851A (es) |
| HR (1) | HRP20050496A2 (es) |
| MA (1) | MA27557A1 (es) |
| MX (1) | MXPA05004779A (es) |
| NO (1) | NO20052796D0 (es) |
| PE (1) | PE20040832A1 (es) |
| PL (1) | PL376867A1 (es) |
| TW (1) | TW200418834A (es) |
| UY (1) | UY28074A1 (es) |
| WO (1) | WO2004043950A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| EA011211B1 (ru) | 2003-11-20 | 2009-02-27 | Янссен Фармацевтика Н. В. | 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы |
| AU2004295058B9 (en) * | 2003-11-20 | 2011-06-30 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| EP1687313A1 (en) * | 2003-11-21 | 2006-08-09 | Bayer Pharmaceuticals Corporation | Indolyl-thien 3,4-b]pyrazin-3-one derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| SG154432A1 (en) | 2004-06-30 | 2009-08-28 | Janssen Pharmaceutica Nv | Quinazolinedione derivatives as parp inhibitors |
| WO2006003150A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| JP4852540B2 (ja) | 2004-06-30 | 2012-01-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのフタラジン誘導体 |
| DE602005026557D1 (de) | 2004-11-17 | 2011-04-07 | Korea Res Inst Chem Tech | 1-ä(6-substituiertes alkoxychinoxalinyl) aminocarbonylü-4-(hetero)arylpiperazinderivate |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| EP2757099B1 (en) | 2005-05-12 | 2017-08-23 | AbbVie Bahamas Limited | Apoptosis promoters |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| HRP20120346T1 (hr) | 2007-03-08 | 2012-05-31 | Janssen Pharmaceutica N.V. | Derivati kinolinona kao parp i tank inhibitori |
| JP5492183B2 (ja) | 2008-03-27 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン |
| WO2010053757A1 (en) * | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| JP2012508250A (ja) * | 2008-11-07 | 2012-04-05 | ワイス・エルエルシー | キノキサリン系のｌｘｒモジュレーター |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MA39784B1 (fr) | 2014-03-26 | 2021-03-31 | Astex Therapeutics Ltd | Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer |
| AU2015238305B2 (en) | 2014-03-26 | 2020-06-18 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| TW201625578A (zh) | 2014-04-18 | 2016-07-16 | 千禧製藥公司 | 喹啉化合物及其用途 |
| CA2974078A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
| JO3695B1 (ar) | 2015-02-10 | 2020-08-27 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين) |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| KR102703498B1 (ko) | 2015-09-23 | 2024-09-04 | 얀센 파마슈티카 엔브이 | 신규 화합물 |
| CN108137546B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途 |
| WO2023050007A1 (en) * | 2021-09-29 | 2023-04-06 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta |
| CR20250160A (es) * | 2022-09-29 | 2025-08-06 | Repare Therapeutics Inc | Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido) carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
-
2003
- 2003-11-05 AR ARP030104059A patent/AR043059A1/es unknown
- 2003-11-10 MX MXPA05004779A patent/MXPA05004779A/es not_active Application Discontinuation
- 2003-11-10 BR BR0316169-2A patent/BR0316169A/pt not_active Application Discontinuation
- 2003-11-10 KR KR1020057008396A patent/KR20050072824A/ko not_active Withdrawn
- 2003-11-10 JP JP2005507146A patent/JP2006509840A/ja active Pending
- 2003-11-10 HR HR20050496A patent/HRP20050496A2/hr not_active Application Discontinuation
- 2003-11-10 AU AU2003290744A patent/AU2003290744A1/en not_active Abandoned
- 2003-11-10 CA CA002505819A patent/CA2505819A1/en not_active Abandoned
- 2003-11-10 PL PL376867A patent/PL376867A1/pl unknown
- 2003-11-10 EP EP03783328A patent/EP1565455A1/en not_active Withdrawn
- 2003-11-10 WO PCT/US2003/036003 patent/WO2004043950A1/en not_active Ceased
- 2003-11-11 TW TW092131443A patent/TW200418834A/zh unknown
- 2003-11-11 PE PE2003001136A patent/PE20040832A1/es not_active Application Discontinuation
- 2003-11-11 UY UY28074A patent/UY28074A1/es not_active Application Discontinuation
-
2005
- 2005-06-09 NO NO20052796A patent/NO20052796D0/no not_active Application Discontinuation
- 2005-06-09 MA MA28322A patent/MA27557A1/fr unknown
- 2005-06-10 EC EC2005005851A patent/ECSP055851A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1565455A1 (en) | 2005-08-24 |
| ECSP055851A (es) | 2005-09-20 |
| MA27557A1 (fr) | 2005-10-03 |
| AU2003290744A1 (en) | 2004-06-03 |
| PE20040832A1 (es) | 2005-01-27 |
| MXPA05004779A (es) | 2005-07-22 |
| BR0316169A (pt) | 2005-09-27 |
| UY28074A1 (es) | 2004-05-31 |
| CA2505819A1 (en) | 2004-05-27 |
| AR043059A1 (es) | 2005-07-13 |
| NO20052796L (no) | 2005-06-09 |
| KR20050072824A (ko) | 2005-07-12 |
| HRP20050496A2 (en) | 2006-06-30 |
| WO2004043950A1 (en) | 2004-05-27 |
| NO20052796D0 (no) | 2005-06-09 |
| JP2006509840A (ja) | 2006-03-23 |
| TW200418834A (en) | 2004-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12006502386B1 (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| IL191865A0 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| IL191864A0 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| AU2003299474A8 (en) | 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders | |
| IL230025A0 (en) | Carbosteril history and mood stabilizers for the treatment of mood disorder | |
| AP2005003283A0 (en) | Indole derivatives useful for the treatment os diseases | |
| NO20052796D0 (no) | Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| PL1599467T3 (pl) | Nowe pochodne cyjanopirydyny użyteczne w leczeniu raka i innych zaburzeń | |
| SI1656346T1 (sl) | 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni | |
| SI2096919T1 (sl) | Substituirani derivati 2,3-dihidroimidazo(1,2-C)kinazolina, uporabni za zdravljenje hiperproliferativnih motenj in bolezni, povezanih z angiogenezo | |
| PL374939A1 (en) | Electrically heated cigarette including controlled-release flavoring | |
| ZA200202542B (en) | Treating sleep disorders using desloratadine. | |
| ZA200107689B (en) | 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders. | |
| AP2005003297A0 (en) | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain | |
| AU7388101A (en) | Indole derivatives useful for the treatment of cns disorders | |
| IL153605A0 (en) | Indole derivatives useful for the treatment of cns disorders | |
| HUP0200520A3 (en) | Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia | |
| IL153254A0 (en) | Indole derivatives useful for the treatment of cns disorders | |
| PT1742947E (pt) | Derivados de piridoindolona substituídos em -6, sua preparação, sua aplicação em terapia | |
| HRP20041159A2 (en) | Combination for the treatment of airway disorders | |
| IL153351A0 (en) | Indole derivatives useful for the treatment of cns disorders | |
| IL153234A0 (en) | Indole derivatives useful for the treatment of cns disorders | |
| SI1294710T1 (en) | Indole derivatives useful for the treatment of cns disorders | |
| SI1305307T1 (en) | Indole derivatives useful for the treatment of cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |